Corrie P, Marshall A, Lorigan P, et al. Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: final results for the AVAST-M Trial. J Clin Oncol 35, 2017 (suppl; abstr 9501).
Nieuwe hoogleraar wil immuuntherapie voor melanomen personaliseren
nov 2020 | Dermato-oncologie, Immuuntherapie